Radiopharm Theranostics Limited (RADX) Research
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Market snapshot
- Symbol
- RADX
- Price
- $4.45
- Day change
- +0.68%
- Market cap
- $47.3M
- P/E ratio
- -1.58x
- 52-week range
- 3.62-16.25
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 3 months
- Analyst price target
- $6.00
Recent news
- Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase 1 clinical trial of its lead prostate cancer candidate...
- Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase 1 clinical trial of its lead prostate cancer candidate...
- Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
RAD 101 is Radiopharm's novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid tumors of different origins.
Peer companies
Recent insider activity
- Voliotis Dimitris — trade (7657334 shares) on 2028-07-01
- HOPPER PAUL — trade (0 shares) on 2026-03-18
- HOPPER PAUL — trade (0 shares) on 2026-03-18
- HOPPER PAUL — trade (0 shares) on 2026-03-18
- HOPPER PAUL — trade (1403723 shares) on 2025-07-01
Open Radiopharm Theranostics Limited (RADX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.